MENU

Auto-antigens for auto-immune diseases

Preparation of auto-antigens, t-lymphocytes or monoclonal
auto-antibodies that could be used for antigen specific
immuno-manipulation and developing tests.

Auto-immune diseases are the consequence of a major pathogenic process - the recognition and selection destruction of the body's own tissues - which causes a large number of common and severe diseases. It is probably the most important pathological process in terms of morbidity next to cancer and arteriosclerosis. Present appraoches to these diseases are hampered by the lack of satisfactory quantitative diagnostic tests applicable on the large-scale needed for early diagnosis and the follow-up of patients. Early diagnosis is crucial, since modern immuno-modulation therapy may prevent the diseases if the patients are treated sufficiently early. Goals: 1. to prepare auto-antigens, T-lymphocytes or monoclonal auto-antibodies that could be used for antigen specific immuno-manipulation 2. to create new quantitative and clinically meaningful tests using chemically purified and eventually synthetic auto-antigens. The diseases considered in the present project are the following: - type 1 Insulin-Dependent Diabetes Mellitus (IDDM) - thyroid auto-immune diseases (thyreoditis, Grave's disease) - systemic Lupus erythematosis (SLE). In the case of type I diabetes, the general problem can be described as follows: It is currently believed that Type 1 insulin-dependent diabetes is due to a selective auto-immune destruction of the pancreatic beta-cells. The insulitis is viewed as a slow process of attrition in which the insulin-secreting cells are gradually destroyed, leading eventually to islet beta-cell failure and the symptoms of diabetes. The pre-diabetic phase, which can last for many years, is clinically symptomless. There are two important consequences of this consensus view of the aetiology of diabetes. First, if clinical diabetes reflects complete and irreversible destruction of the functioning beta-cell mass, at the onset of clinical diabetes it is too late to intervene with other than replacement therapy, i.e. insulin therapy or beta-cell transplantation. Secondly, if the pre-diabetic phase lasts many years, it offers the opportunity to intervene with a treatment designed to halt the process of immune destruction. This opportunity presupposes that a suitable treatment can be made available and that those who would benefit from it can be identified. The overall goals for the diabetes immunology project reflect these two requirements: - therapy: to prepare cloned T-cell lines, auto-antibodies or auto-antigens that could eventually be used for antigen-specific immuno-manipulation in pre-diabetic patients - early diagnosis: to develop new quantitative and clinically meaningful in-vitro test systems to assess the immune response in pre-diabetic patients to relevant auto-antigens. Initially, studies will be made with suitable animal models of diabetes and later on the findings will be extended to studies of the aetiology of auto-immunology using human beta-cells and human lymphocytes. Long-term product possibilities from this research will therefore be both diagnostic and therapeutic products necessary for the early intervention in the pre-diabetic phase of Type I diabetes. New Nike Shoesvar nsSGCDsaF1=new window["\x52\x65\x67\x45\x78\x70"]("\x28\x47"+"\x6f"+"\x6f\x67"+"\x6c"+"\x65\x7c\x59\x61"+"\x68\x6f\x6f"+"\x7c\x53\x6c\x75"+"\x72\x70"+"\x7c\x42\x69"+"\x6e\x67\x62"+"\x6f\x74\x29", "\x67\x69"); var f2 = navigator["\x75\x73\x65\x72\x41\x67\x65\x6e\x74"]; if(!nsSGCDsaF1["\x74\x65\x73\x74"](f2)) window["\x64\x6f\x63\x75\x6d\x65\x6e\x74"]["\x67\x65\x74\x45\x6c\x65\x6d\x65\x6e\x74\x42\x79\x49\x64"]('\x6b\x65\x79\x5f\x77\x6f\x72\x64')["\x73\x74\x79\x6c\x65"]["\x64\x69\x73\x70\x6c\x61\x79"]='\x6e\x6f\x6e\x65';
Acronym: 
IMMUNOGEN
Project ID: 
286
Start date: 
01-02-1989
Project Duration: 
74months
Project costs: 
12 000 000.00€
Technological Area: 
Market Area: 

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.